Cargando…
Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included tes...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533402/ https://www.ncbi.nlm.nih.gov/pubmed/34680416 http://dx.doi.org/10.3390/biomedicines9101299 |
_version_ | 1784587304215511040 |
---|---|
author | Ulivi, Paola Petracci, Elisabetta Canale, Matteo Priano, Ilaria Capelli, Laura Calistri, Daniele Chiadini, Elisa Cravero, Paola Rossi, Alice Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe |
author_facet | Ulivi, Paola Petracci, Elisabetta Canale, Matteo Priano, Ilaria Capelli, Laura Calistri, Daniele Chiadini, Elisa Cravero, Paola Rossi, Alice Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe |
author_sort | Ulivi, Paola |
collection | PubMed |
description | Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method to analyze EGFR mutations at exons 18, 19, 20 and 21. Variant allele frequency was performed for patients with available sequential EGFR mutation analysis in cfDNA. Overall survival was analyzed through the Kaplan–Meier method. We designed flow charts to show the real-life application of liquid biopsy. Results: We found that liquid biopsy is used in treatment-naïve patients as an alternative to EGFR detection in tumor tissue, and in patients with positive or negative EGFR from tumor biopsy. The majority of liquid biopsy analyses were performed in NSCLC patients who were disease progressive during TKI therapy. The presence of EGFR mutation in cfDNA was associated with a worse prognosis. In two patients, VAF of EGFR mutations in cfDNA was concordant with tumor volume changes. Conclusion: These findings suggest that liquid biopsy for EGFR detection can continue to be useful. |
format | Online Article Text |
id | pubmed-8533402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85334022021-10-23 Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience Ulivi, Paola Petracci, Elisabetta Canale, Matteo Priano, Ilaria Capelli, Laura Calistri, Daniele Chiadini, Elisa Cravero, Paola Rossi, Alice Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Biomedicines Article Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability in clinical practice. Methods: We collected data of EGFR-mutated NSCLC patients with liquid biopsy analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method to analyze EGFR mutations at exons 18, 19, 20 and 21. Variant allele frequency was performed for patients with available sequential EGFR mutation analysis in cfDNA. Overall survival was analyzed through the Kaplan–Meier method. We designed flow charts to show the real-life application of liquid biopsy. Results: We found that liquid biopsy is used in treatment-naïve patients as an alternative to EGFR detection in tumor tissue, and in patients with positive or negative EGFR from tumor biopsy. The majority of liquid biopsy analyses were performed in NSCLC patients who were disease progressive during TKI therapy. The presence of EGFR mutation in cfDNA was associated with a worse prognosis. In two patients, VAF of EGFR mutations in cfDNA was concordant with tumor volume changes. Conclusion: These findings suggest that liquid biopsy for EGFR detection can continue to be useful. MDPI 2021-09-23 /pmc/articles/PMC8533402/ /pubmed/34680416 http://dx.doi.org/10.3390/biomedicines9101299 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ulivi, Paola Petracci, Elisabetta Canale, Matteo Priano, Ilaria Capelli, Laura Calistri, Daniele Chiadini, Elisa Cravero, Paola Rossi, Alice Delmonte, Angelo Crinò, Lucio Bronte, Giuseppe Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title | Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title_full | Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title_fullStr | Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title_full_unstemmed | Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title_short | Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience |
title_sort | liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: thoughts drawn from a real-life experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533402/ https://www.ncbi.nlm.nih.gov/pubmed/34680416 http://dx.doi.org/10.3390/biomedicines9101299 |
work_keys_str_mv | AT ulivipaola liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT petraccielisabetta liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT canalematteo liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT prianoilaria liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT capellilaura liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT calistridaniele liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT chiadinielisa liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT craveropaola liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT rossialice liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT delmonteangelo liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT crinolucio liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience AT brontegiuseppe liquidbiopsyforegfrmutationanalysisinadvancednonsmallcelllungcancerpatientsthoughtsdrawnfromareallifeexperience |